The recurrence of variations in pivotal genes like TP53 and KRAS, both of which play central roles as tumor suppressors and oncogenes, respectively, supports the biological relevance of the identified alterations and validates the robustness of the variant prioritization strategy implemented in this study. This evidence concerns the gene KRAS and neoplasm.